This site is intended for health professionals only

Genentech’s profit growth slows

teaser

Biotechnology firm Genentech has only just met Wall Street expectations as the firm renowned for its phenomenal growth posted a 6% rise in fourth-quarter profits.

Last year, the company revealed a 75% increase over the same period, and investors have become accustomed to quarterly growth in the high double digits.

The company earned $632m compared with a profit of $594m during the same period a year earlier, while revenue rose to $2.97bn from $2.71bn.

Analysts have been concerned that the market for the San Francisco-based company’s top-selling cancer drug Avastin was becoming saturated.

And latest figures show that sales growth for the drug has slowed, with sales hitting $603m during the fourth quarter, which is below the $616m which had been predicted by Wall Street.

Prospects for greater growth were hit last month when a Food and Drug Administration panel decided not to recommend the drug for expanded use in breast cancer patients.

Rituxan (rituximab), a treatment for rheumatoid arthritis and non-Hodgkin’s lymphoma, is Genentech’s second biggest source of revenue. Sales of the drug brought in $596m last quarter, which is up 6% from the same period a year ago.

Meanwhile, the firm’s breast cancer drug Herceptin (trastuzumab) brought in $327m for the quarter, which is a 2% increase.

Copyright © PA Business 2008

Genentech

Take part in our prize-draw survey






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x